Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 656,862
  • Shares Outstanding, K 97,169
  • Annual Sales, $ 40 K
  • Annual Income, $ -170,060 K
  • 60-Month Beta 1.75
  • Price/Sales 14,507.56
  • Price/Cash Flow N/A
  • Price/Book 4.65
Trade MRSN with:

Options Overview Details

View History
  • Implied Volatility 105.28% ( -35.71%)
  • Historical Volatility 53.26%
  • IV Percentile 73%
  • IV Rank 35.32%
  • IV High 200.14% on 08/02/22
  • IV Low 53.49% on 09/28/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 31
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 795
  • Open Int (30-Day) 895

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.03
  • Number of Estimates 4
  • High Estimate 0.43
  • Low Estimate -0.47
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +95.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.08 +11.18%
on 09/23/22
8.34 -18.92%
on 09/08/22
-0.89 (-11.63%)
since 08/30/22
3-Month
4.50 +50.22%
on 07/05/22
8.34 -18.92%
on 09/08/22
+2.14 (+46.32%)
since 06/30/22
52-Week
2.68 +152.24%
on 05/12/22
10.01 -32.47%
on 11/08/21
-2.67 (-28.31%)
since 09/30/21

Most Recent Stories

More News
Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

MRSN : 6.76 (+5.30%)
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

GSK : 29.43 (+0.24%)
AMGN : 225.40 (-1.32%)
VRTX : 289.54 (-1.11%)
CCXI : 51.66 (unch)
MRSN : 6.76 (+5.30%)
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.

GSK : 29.43 (+0.24%)
AMGN : 225.40 (-1.32%)
VRTX : 289.54 (-1.11%)
CCXI : 51.66 (unch)
MRSN : 6.76 (+5.30%)
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

MRSN : 6.76 (+5.30%)
MNKD : 3.09 (+3.34%)
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

Approaching full enrollment in UPLIFT clinical trial; initiated patient screening in UP-NEXT clinical trialCleared INDs for XMT-1660 and XMT-2056Enhanced...

MRSN : 6.76 (+5.30%)
Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

GSK receives exclusive global license option for XMT-2056 Mersana to receive $100 million upfront option purchase feeIf GSK exercises its option, Mersana...

MRSN : 6.76 (+5.30%)
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on...

MRSN : 6.76 (+5.30%)
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

AMYT : 6.92 (-3.08%)
MRSN : 6.76 (+5.30%)
Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...

MRSN : 6.76 (+5.30%)
How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%

The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

MRSN : 6.76 (+5.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 7.48
2nd Resistance Point 7.20
1st Resistance Point 6.98
Last Price 6.76
1st Support Level 6.48
2nd Support Level 6.20
3rd Support Level 5.98

See More

52-Week High 10.01
Fibonacci 61.8% 7.21
Last Price 6.76
Fibonacci 50% 6.35
Fibonacci 38.2% 5.48
52-Week Low 2.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar